The results indicate that the CPR complex interrupts the endosomal pathway, effectively reducing the colocalization of delivered siRNA with lysosomes and enhancing gene regulation efficiency, suggesting that the CPR nanocarrier design could serve as a versatile platform for targeted RNA delivery.
Abstract
ABSTRACT Small interfering RNA (siRNA) has shown great potential for treating various genetic diseases, but lysosomal degradation limits its bioavailability. Here, we present the design of a Channel‐PNA‐siRNA (CPR) complex that facilitates endosomal escape by actively inducing osmotic rupture of the endosomes. Our design utilizes the transmembrane domain of the M2 proton channel (M2TM) to facilitate proton influx into the liposome while serving as an anchor for siRNA; this surface tethering is mediated by a peptide nucleic acid (PNA) linker that enables stable, non‐covalent binding. Our results indicate that the CPR complex interrupts the endosomal pathway, effectively reducing the colocalization of delivered siRNA with lysosomes and enhancing gene regulation efficiency. Furthermore, we demonstrate dual‐target gene knockdown using CPR‐tethered liposomes by encapsulating additional siRNAs in the empty cavity of the liposome. These findings highlight the therapeutic potential of modulating the endosomal pH environment to prevent lysosomal degradation, suggesting that the CPR nanocarrier design could serve as a versatile platform for targeted RNA delivery.
Lipid nanoparticles (LNPs) have transformed nucleic acid delivery for vaccines and gene therapies, yet their efficiency remains limited by incomplete endosomal escape. While experimental studies have revealed endosomal membrane disruption facilitating cytosolic release, the molecular basis of this process remains poorl...
A. P. Singh, Kana Shibata, Yusuke Miyazaki et al.· bioRxiv· 0 citations
ABSTRACT Lipid nanoparticles (LNPs) have enabled the clinical application of RNA therapeutics, including approved mRNA vaccines and siRNA medicines. However, their predominant accumulation in liver after systemic administration and inefficient endosomal escape remain key bottlenecks for productive cytosolic delivery an...
Seong Gi Lim, Min-Ju Lee, Yiming Wang et al.· Advancement of science· 0 citations
Understanding the physicochemical factors that govern siRNA nanocarrier assembly is essential for the rational design of effective delivery systems. By optimizing various lipid compositions, cholesterol content and PEG length we created a peptide-functionalized cationic liposomal platform made of DOPE/TAP lipids with c...
P. Białecki, S. Braccia, T. Makowski et al.· bioRxiv· 0 citations
Small interfering RNA (siRNA) and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated Protein 9 (Cas9) complexes are effective approaches to temporarily downregulate protein expression via post-transcription RNA interference or permanently altering protein expression via editing gen...
Abdulelah Alhazza, Sorour Khayyatnejad Shoushtari, Hasan Uludağ et al.· Frontiers in Nanotechnology· 0 citations
Small interfering RNA (siRNA) therapeutics have emerged as a transformative approach for sequence-specific gene silencing, offering the potential to treat a broad spectrum of diseases by selectively suppressing disease-associated genes. However, the clinical translation of siRNA remains limited by rapid enzymatic degra...
G. S. Amrish Varshan, S. Namasivayam· Nanomedicine: Nanotechnology...· 0 citations
Oligonucleotide therapeutics have great potential for the treatment of previously "undruggable" human diseases; however, their broad utility is limited by challenges in delivery and achieving sufficient endosomal escape. Systemic delivery of antisense oligonucleotides (ASOs) results in their primary accumulation in the...
Priyanka Mangla, Emma Kay, M. J. Munson et al.· Nucleic Acid Therapeutics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.